Epinephrine Inhalation Aerosol USP: For Evaluation Of Efficacy And Safety In Asthma Patients

Inclusion Criteria: * Patients with documented asthma, requiring inhaled epinephrine or beta 2-agonist treatment. * No significant changes in asthma therapy and no asthma-related hospitalization or emergency visits, within 4 weeks prior to Screening * Can tolerate withholding treatment with inhaled bronchodilators and other allowed medications for the minimum washout period. * Demonstrating a Screening Baseline FEV1 that is 50 - 90% of predicted normal value. * Demonstrating at least a 12% Airway Reversibility. * Demonstrating satisfactory techniques in the use of metered-dose inhaler and a hand held peak expiratory flow meter. * Female patients of child-bearing potential must be non-pregnant and non-lactating at Screening and throughout the study, and must use an acceptable method of contraception during the study. Exclusion Criteria: * A smoking history of 10-pack years, or having smoked within 12 months of screening. * Any current or past medical conditions that, per investigator discretion, might significantly affect responses to the study drugs, other than asthma. * Concurrent clinically significant diseases. * Known intolerance or hypersensitivity to any component of the study drugs. * Recent infection of the respiratory tract, before screening. * Use of prohibited medications. * Having been on other investigational drug/device studies in the last 30 days prior to screening. * Known or highly suspected substance abuse.